Insider Selling: Privia Health Group, Inc. (NASDAQ:PRVA) CFO Sells 5,630 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA - Get Free Report) CFO David Mountcastle sold 5,630 shares of the stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the completion of the sale, the chief financial officer now directly owns 179,676 shares in the company, valued at approximately $4,021,148.88. This trade represents a 3.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Privia Health Group Stock Up 1.2 %

NASDAQ:PRVA traded up $0.26 during trading hours on Tuesday, reaching $21.74. 1,130,941 shares of the company's stock were exchanged, compared to its average volume of 782,479. The company has a market capitalization of $2.62 billion, a P/E ratio of 217.42, a price-to-earnings-growth ratio of 3.47 and a beta of 0.88. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.04. The business's 50-day simple moving average is $23.71 and its two-hundred day simple moving average is $21.36.

Wall Street Analyst Weigh In

Several brokerages have commented on PRVA. Needham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of Privia Health Group in a research note on Friday, March 21st. Canaccord Genuity Group lifted their target price on Privia Health Group from $29.00 to $30.00 and gave the company a "buy" rating in a research note on Friday, February 28th. JMP Securities set a $29.00 price target on Privia Health Group in a research note on Friday, February 28th. Stephens restated an "overweight" rating and set a $26.00 price objective on shares of Privia Health Group in a research note on Thursday, January 2nd. Finally, Piper Sandler increased their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $26.67.

Remove Ads

Institutional Investors Weigh In On Privia Health Group

Several large investors have recently modified their holdings of the stock. First Horizon Advisors Inc. raised its position in shares of Privia Health Group by 53.8% during the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company's stock worth $35,000 after purchasing an additional 632 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Privia Health Group by 7,833.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company's stock worth $47,000 after buying an additional 2,350 shares during the period. Financial Management Professionals Inc. acquired a new stake in Privia Health Group during the 4th quarter worth about $51,000. Quarry LP lifted its stake in Privia Health Group by 344.6% during the third quarter. Quarry LP now owns 3,268 shares of the company's stock valued at $60,000 after buying an additional 2,533 shares in the last quarter. Finally, Neo Ivy Capital Management acquired a new position in shares of Privia Health Group in the third quarter worth about $66,000. 94.48% of the stock is owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.